Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
| ▸ | SPHK2 | Q9NRA0 | 2/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.44 |
| ▸ | AQP4 | P55087 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.43 |
| ▸ | RARA | P10276 | 1/20 | 0.42 |
| ▸ | RARB | P10826 | 1/20 | 0.42 |
| ▸ | RARG | P13631 | 1/20 | 0.42 |
| ▸ | GCK | P35557 | 1/20 | 0.42 |
| ▸ | ALKBH1 | Q13686 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2664647 | 0.85 | GCK (0.49) | KDM4ECSNK2A2CSNK2A1RAB9AAQP4 | |
| SCHEMBL2664668 | 0.79 | LMNA (0.47) | KDM4ERAB9AAQP4LMNARARA | |
| SCHEMBL2664914 | 0.79 | GCK (0.52) | KDM4ECSNK2A2CSNK2A1RAB9AAQP4 | |
| SCHEMBL2664680 | 0.79 | GCK (0.64) | KDM4ECSNK2A2CSNK2A1RAB9ALMNA | |
| SCHEMBL2664666 | 0.76 | KDM4E (0.42) | KDM4ESPHK2RAB9ASPHK1AQP4 | |
| SCHEMBL2664606 | 0.76 | SGMS2 (0.52) | CSNK2A2CSNK2A1SPHK2SPHK1FFAR1 | |
| SCHEMBL2664858 | 0.75 | GCK (0.57) | KDM4ECSNK2A2CSNK2A1SPHK2SPHK1 | |
| SCHEMBL2664867 | 0.75 | PLAU (0.47) | KDM4ECSNK2A2CSNK2A1SPHK2SPHK1 | |
| SCHEMBL2664602 | 0.74 | GCK (0.56) | CSNK2A2CSNK2A1SPHK2SPHK1FFAR1 | |
| SCHEMBL2664864 | 0.74 | GCK (0.53) | CSNK2A2CSNK2A1SPHK2RAB9ASPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-7951830-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2011-05-31 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | ASTRAZENECA AB (SE) | 2009-09-10 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-7524957-B2 | Compounds effecting glucokinase | ASTRAZENECA AB (SE) | 2009-04-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-20080207636-A1 | Compounds Effecting Glucokinase | ASTRAZENECA AB (SE) | 2008-08-28 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
| US-7390908-B2 | Such as 2-[3,5-Di(2-chlorobenzyloxy)benzoyl)amino]-thiazole; for treatment of diabetes | ASTRAZENECA AB (SE) | 2008-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207636-A1 | Compounds Effecting Glucokinase | GCKR, GCK, SLC5A2 | KDM4E 2280/4885CSNK2A2 444/4885CSNK2A1 432/4885 |
| US-20090227592-A1 | COMPOUNDS EFFECTING GLUCOKINASE | GCKR, GCK, SLC5A2 | KDM4E 2280/4885CSNK2A2 444/4885CSNK2A1 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.